Kieran O'Kane - 20 Feb 2026 Form 4 Insider Report for BIODESIX INC (BDSX)

Reporting relationship: Chief Commercial Officer
Issuer ticker: BDSX
Reported as of: 20 Feb 2026
Net transaction value: -$6,835
SEC form: 4
Accepted by SEC: 23 Feb 2026, 20:22:24 UTC
Prior SEC filing: 11 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Robin H. Cowie as Attorney-in-Fact for Kieran O'Kane

Key filing fact

Kieran O'Kane filed Form 4 for BIODESIX INC (BDSX) on 23 Feb 2026.

Key facts

This page summarizes Kieran O'Kane's Form 4 filing for BIODESIX INC (BDSX).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 23 Feb 2026, 20:22.

Change

Previous filing in this sequence was filed on 11 Feb 2026.
Current net transaction value: -$6,835.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001828131 Primary reporting owner

O'Kane Kieran

Relationship: Chief Commercial Officer
Address: 919 WEST DILLON RD, LOUISVILLE
Signature: /s/ Robin H. Cowie as Attorney-in-Fact for Kieran O'Kane
Signature date: 23 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BDSX transaction

Common Stock

Options Exercise

Transaction value
Shares: +1,469
Change %: +17%
Price
Shares after: 10,354
Date: 20 Feb 2026
Ownership: Direct
Footnotes: F1

BDSX transaction

Common Stock

Sale

Transaction value: $6,835
Shares: -535
Change %: -5.2%
Price: $12.78
Shares after: 9,819
Date: 23 Feb 2026
Ownership: Direct
Footnotes: F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BDSX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -1,469
Change %: -25%
Price: $0.000000
Shares after: 4,406
Date: 20 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,469
Exercise price
Footnotes: F1, F4, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

Footnote F2

These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.

Footnote F3

The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $12.58 to $13.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F4

These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025.

Footnote F5

These RSUs vest in a series of four successive equal annual installments measured from February 20, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.